Lundbeck gets 2nd go at FDA for schizophrenia drug; Aurobindo goes generic on Lexapro;

 @FiercePharma: Sanofi workers to strike as day of reckoning nears. More | Follow @FiercePharma

> An analysis of 133 print and broadcasting ads for four different medicines that were switched to over-the-counter sales found that more of them touted benefits after the switch than when they were sold by prescription. Story 

> Danish drugmaker Lundbeck says it will get a new meeting with the FDA next year for the resubmission for its schizophrenia treatment, aripiprazole depot formulation. Story 

> Aurobindo Pharma has final approval from the FDA to make and market a generic of Forest Laboratories' anti-depressant Lexapro. Item

> The DEA will revoke the license of two CVS drugstores in Florida over "suspicious sales" of oxycodone and other painkillers. Story

> Pfizer ($PFE) is using a new cloud-based software system for its supply chain operations. Story

Biotech News

 @FierceBiotech: D-Day for Sanofi multiples cerlosis drug Aubagio as deep R&D cuts loom. Story | Follow @FierceBiotech

 @JohnCFierce: Lundbeck, Otsuka scramble to get antipsychotic back on FDA track--(competing with Alkermes). Article | Follow @JohnCFierce

 @RyanMFierce: My take on Illumina's alliance with Partners HealthCare to combine sequencing and software. Story | Follow @RyanMFierce

> UNC biotech spinoff grabs J&J deal and $16M A round for diabetic nephropathy drug. Story

> GlaxoSmithKline anti-smoking drug combats addictive cravings. Report

> Sanofi's dengue fever vaccine trial flop rattles the experts. News

Medical Device News

 @FierceMedDev: J&J has settled the first three lawsuits involving failure of its ASR hip implants. Thousands more to come. Release | Follow @FierceMedDev

 @MarkHFierce: bioMerieux got slapped with an FDA warning letter for quality violations regarding a NC Dx manufacturing facility. Warning Letter | Follow @MarkHFierce

 @DamianFierce: Berkeley's Ekso Bionics is looking to expand the use of its robotic walking aid. Report | Follow @DamianFierce

> IntraPace preps anti-obesity device for U.S. regulatory path. More

> PrimeraDx snags CE marks for assays. News

Biomarkers News

> Janssen's Remicade attacks inflammation to beat depression. Article

> Increased antibody levels tag raised rheumatoid arthritis risk. Story

> Researchers develop genetic test to fine-tune warfarin dose. Item

> Breast cancer protein pinpoints survival chances. More

Drug Delivery News

> Hopkins cracks blood-brain barrier with nanobeads. More

> Sublingual opioid addiction therapy moves closer to market. Report

> Silence breaks out with preclinical data on Atu111. Story

> InSite eyes next-generation DuraSite delivery. Article

> Anti-HIV vaginal ring shows hints of efficacy. More

> AZ goes Down Under for cancer conjugate deal. Item

And Finally... Cosmetics behemoth Lancôme has received a warning letter from the FDA over what the agency says are unacceptable medical claims for some its anti-aging creams, such as that they boost "the activity of genes and stimulates the production of youth proteins." Warning letter

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.